Avecho Biotechnology Limited (ASX:AVE)
Australia
· Delayed Price · Currency is AUD 0.0050
+0.0010 (25.00%)
Apr 30, 2025, 4:10 PM AEST
Avecho Biotechnology Revenue
In the year 2024, Avecho Biotechnology had annual revenue of 1.13M AUD with 139.19% growth. Avecho Biotechnology had revenue of 820.49K in the half year ending December 31, 2024, with 121.14% growth.
Revenue
1.13M
Revenue Growth
+139.19%
P/S Ratio
11.19
Revenue / Employee
75.51K
Employees
15
Market Cap
12.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13M | 659.12K | 139.19% |
| Dec 31, 2023 | 473.55K | -655.71K | -58.07% |
| Dec 31, 2022 | 1.13M | 335.66K | 42.30% |
| Dec 31, 2021 | 793.60K | 408.97K | 106.33% |
| Dec 31, 2020 | 384.63K | -3.85M | -90.92% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Telix Pharmaceuticals | 783.21M |
| Ramsay Health Care | 17.12B |
| Ansell | 3.00B |
| Mesoblast | 9.16M |